TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06411288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by intravenous (IV) infusion.
Study: NCT05714085
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for vericiguat administered orally once daily in tablet form
Study: NCT06132893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo taken once daily
Study: NCT06312020
Drug: HZN-1116
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Administration
Study: NCT06312020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Administration
Study: NCT05118672
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to this group will receive one (01) experimental drug film-coated tablet every eight (08) hours for three (03) days (nine \[09\] dosage administration). Subjects will be instructed to, thereafter, maintain treatment at the same dosage (one \[01\] film-coated tablet every eight \[08\] hours) in case of persistence of symptoms, discontinuing treatment when they present with no symptoms.
Study: NCT06588686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04791332
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered orally.
Study: NCT04799275
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04799275
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05197049
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by SC injection.
Study: NCT06496178
Drug: Investigator's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab
Study: NCT06058377
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06058377
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05222009
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhG-CSF, 3mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.
Study: NCT05222009
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhG-CSF, 6mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.
Study: NCT04947826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05493228
Drug: Precedex Injectable Product
Normalized name: Precedex Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precedex activates 2-adrenoceptors, and causes the decrease of sympathetic tone, with attenuation of the neuroendocrine and hemodynamic responses to anesthesia and surgery; it reduces anesthetic and opioid requirements; and causes sedation and analgesia. it is used before and/or during surgical
Study: NCT05124002
Drug: Recombinant Human Adenovirus Type 5
Normalized name: adenovirus, type 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: H101 will be intratumorally injected 3 days before HAIC. Dosage of H101: 1 vial (5.0 × 10\^11 vp) if the maximum diameters of lesion ≤ 5 cm, 2 vials (1.0 × 10\^12 vp) if the maximum diameters of lesion ≤ 10 cm, 3 vials (1.5 × 10\^12 vp) if the maximum diameters of lesion is \> 10 cm.
Study: NCT06559306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo tablets will be administered orally.
Study: NCT06559306
Drug: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI/SNRI will be administered orally.
Study: NCT06700720
Drug: Dose 1 YN001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1 YN001 will be administered on Day 1 and Day 5 of each week from Week 1 to Week 12, and on Day 1 of Week 13, 25 times in total.
Study: NCT06700720
Drug: Dose 2 YN001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 2 YN001 will be administered on Day 1 of each week from Week 1 to Week 13, 13 times in total.
Study: NCT04844411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered orally.
Study: NCT04782505
Drug: DWJ1248
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camostat mesylate Tablet from Daewoong
Study: NCT06449651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administrated intravenously.
Study: NCT04655807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered as SC injection.
Study: NCT06095102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally.
Study: NCT05541315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered orally.
Study: NCT06247241
Drug: VMB-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: VMB-100 is administered as intrasphincteric injection in the urethra sphincter
Study: NCT04937543
Drug: inhaled beclametasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adding belcamethasone to standard of care for Covid 19 positive patients
Study: NCT05731050
Drug: NM8074
Approvals — FDA: no, EMA: no, PMDA: no
Description: NM8074 will be administered as an intravenous infusion. All enrolled subjects will receive a dose of 15 mg/kg NM8074 once every two weeks for a total of 6 doses from Day1 to Day 84.~For Soliris-treated PNH subjects, admission and dosing of NM8074 on Day 1 should be scheduled to coincide with the next scheduled dose of Soliris (i.e., 14 ± 2 days after the last Soliris dose). Soliris should NOT be administered on Day 1 or at any time thereafter during course of the study.~Subjects in the treatment groups will receive a dose of 15 mg/kg of NM8074 on Day 1, which will be administered during the study visit by the site staff. During the remainder of the treatment period, subjects will be given another 15 mg/kg dose every two weeks at approximately the same time. On days of scheduled study visits at the Investigation Site, the dose must be administered after blood work is completed.
Study: NCT06138132
Drug: Standard lymphodepletion regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard lymphodepletion regimen
Study: NCT06477991
Drug: Tireilizumab（PD-1 inhibitor）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant immunotherapy phase :~1. Pharmaceuticals: Tireilizumab: 200mg, intravenous infusion, Q3W, at least 4 cycles, the number of specific neoadjuvant immunotherapy cycles was determined according to the results of MRD dynamic monitoring.~2. MRD dynamic monitoring time node: dynamic monitoring at the initial diagnosis and after the fourth cycle of neoadjuvant immunotherapy. Blood monitoring points were 1-2 weeks after immunotherapy. If the two consecutive MRDs were negative, the watch and wait strategy was adopted. If the MRD was still positive after 8 cycles of neoadjuvant immunotherapy, surgical treatment was performed.
Study: NCT05803902
Drug: Experimental drug 9MW1911
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental drug administered with IV infusion
Study: NCT05803902
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered with IV infusion
Study: NCT06642363
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group will take one capsule containing corn starch in a wrapped and covered form and the appearance of ASX supplementation (blinding).
Study: NCT04904237
Drug: Aza-Ven-allo-HSCT
Normalized name: Apis mellifera ven protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: aaa-ven treatment followed by allo-HCTS with reduced toxicity conditioning (RTC) of Fludarabine, Busulifan and Melphalan
Study: NCT05964647
Drug: LSD (150 µg) + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: LSD (150 µg) per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)
Study: NCT05964647
Drug: Placebo + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo (Capsules containing mannitol looking identical to the other drugs)~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)
Study: NCT05753007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution
Study: NCT06050577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weeks 1-4: 3 mg of oral placebo once daily. Weeks 5-52: 7 mg of placebo once daily as maintenance dose. Dose may be increased to 14 mg of placebo once daily as maintenance dose after 2 months if glucose levels are out of range.
Study: NCT05306444
Drug: CLN-418
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration
Study: NCT05498428
Drug: Direct Oral Anticoagulant (DOAC)
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOAC will be administered orally.
Study: NCT05498428
Drug: Low Molecular Weight Heparin (LMWH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH will be administered subcutaneously.
Study: NCT05665608
Drug: Optimal Medical Therapy (OMT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated according to Optimal Medical Therapy defined by the following guidelines:~1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes~2. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
Study: NCT04628026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered in Induction cycle 1, Induction cycle 2 and in the chemo consolidation therapy in addition to the standard chemotherapy
Study: NCT06132958
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m\^2 of doxorubicin by IV Infusion
Study: NCT06343298
Drug: MANP
Normalized name: Multimineral/Multivitamin Oral Tablet [MANPOWER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MANP (modified atrial natriuretic peptide) is a peptide that is being developed for treatment of difficult to control/resistant hypertension.
Study: NCT04745026
Drug: GWP42003-P
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: GWP42003-P oral solution (100 milligrams per milliliter \[mg/mL\] cannabidiol \[CBD\] in sesame oil with anhydrous ethanol, ethanol \[10% v/v\] sweetener \[sucralose\], and strawberry flavoring), administered twice a day (morning and evening)
Study: NCT04745026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo to match GWP42003-P oral solution containing sesame oil with anhydrous ethanol, sweetener (sucralose), strawberry flavoring, and beta carotene, administered twice a day (morning and evening)
Study: NCT06544616
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered intramuscularly.
Study: NCT05552157
Drug: Matching Placebo (Remternetug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as subcutaneous injection of placebo every 12 weeks
Study: NCT05937581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% w/v NaCI, IV Administration
Study: NCT05090891
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered QD orally.
Study: NCT06517563
Drug: VMX-C001
Approvals — FDA: no, EMA: no, PMDA: no
Description: VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
Study: NCT06517563
Drug: UFH
Normalized name: Ibrufhalal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractionated Heparin
Study: NCT05268497
Drug: Antidepressant
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant will be administered orally.
Study: NCT06280716
Drug: Topical Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Corticosteroid
Study: NCT05996471
Drug: Standard of care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-baseline SOC antiretroviral therapy (ART) will be administered.
Study: NCT06049017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet will be administered orally.
Study: NCT05269316
Drug: IMP9064
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMP9064 Monotherapy administered for 21 days
Study: NCT05702034
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally
Study: NCT05864365
Drug: ATH434
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATH434 taken by mouth two times per day
Study: NCT06635980
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive SOC chemotherapy
Study: NCT05327816
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as intramuscular injection.
Study: NCT06799741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: (0.9% saline intravenous solution) 12:2
Study: NCT05361382
Drug: 18F-MK-6240 radiopharmaceutical
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-6240 is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 5 millicuries of the radiopharmaceutical.
Study: NCT05762471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive GSBR-1290 or matching Placebo
Study: NCT06630286
Drug: ISL/LEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally
Study: NCT06630286
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally
Study: NCT06630286
Drug: PTM B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally
Study: NCT06630286
Drug: PTM ISL/LEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally
Study: NCT05930002
Drug: Standared managment
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Vitamin C 500mg tablet twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75mg tablet once daily for two weeks
Study: NCT05042362
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo orally once daily
Study: NCT06283836
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: monitored anesthesia care (sedation)
Study: NCT05610163
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05610163
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05906303
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provide normal saline to serve as a placebo
Study: NCT05970783
Drug: Jincaopian Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jincaopian Tablets 0.2g tid p.o.
Study: NCT04848116
Drug: HuMax-IL8
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuMax-IL8 is an investigational drug in this study.
Study: NCT05085808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the placebo arm.
Study: NCT06619210
Drug: HL231 Dose 1/2/3/4
Approvals — FDA: no, EMA: no, PMDA: no
Description: HL231 Solution for Inhalation, dose 1/2/3 (Part A) , dose 2/4（Part B） single dose, oral inhalation by PARI BOY nebulizer
Study: NCT05564403
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05564403
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05480306
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90-min IV infusion of irinotecan, leucovorin, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks
Study: NCT05480306
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 hour IV infusion of oxaliplatin, folinic acid, and fluorouracil followed by a continuous 46-hour infusion of fluorouracil every two weeks
Study: NCT06276374
Drug: Patients who are scheduled to undergo carotid artery stenting
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Arm A : Single antiplatelet therapy (SAPT) with aspirin or clopidogrel~  - 1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.)→ Randomization → 11 months of single antiplatelet therapy (100mg aspirin q.d. or 75mg clopidogrel q.d.)~* Arm B : Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel - 1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.) → Randomization → 11 months of dual antiplatelet therapy (100mg aspirin q.d. and 75mg clopidogrel q.d.)
Study: NCT04337450
Drug: SOC
Normalized name: Isocet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 nucleos(t)ide reverse transcriptase inhibitor (NRTI) and a third (anchor) drug (either an integrase strand transfer inhibitor (INSTI), a protease inhibitor (PI) or a non- nucleoside reverse transcriptase inhibitor (NNRTI)
Study: NCT05879926
Drug: Ovarian Function Suppression + Aromatase Inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor co-administered with a GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
Study: NCT04633213
Drug: HBM9036 0.25% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic Solution
Study: NCT04633213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic Solution
Study: NCT06127940
Drug: Temporary Stopping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary stop of sotorasib during SBRT
Study: NCT05379790
Drug: CAPOX
Normalized name: Capecitabine and Oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine 1000 mg/m2 twice daily day 1-14 (per os), and Oxaliplatin 130 mg/m2 on day 1 IV infusion.
Study: NCT05746559
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single weight-based dose of placebo via intravenous infusion.
Study: NCT05567835
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2600 mg/m2 IV over 26 hours (+/-1 hour) CI with home pump Day 1,15
Study: NCT05567835
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg mg/m2 IV over 2 hours Day 1,15
Study: NCT06469944
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered via oral tablet.
Study: NCT06469944
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered via IV infusion.
Study: NCT05458479
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants in the study will receive open-label treatment with orally administered fluoxetine for the full duration of the 16-week trial. Fluoxetine is a selective serotonin reuptake inhibitor. It is approved for the management of major depressive disorder in adults.
Study: NCT05728645
Drug: Multiple Electrolytes injection of 5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Multiple Electrolytes injection of 5ml/kg before induction of general anesthesia
Study: NCT05897385
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal 20ml of 0.9% normal saline
Study: NCT05641064
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of saline starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion
Study: NCT05621759
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nitrogen mustard alkylating agent produced by Bristol-Myers Squibb.
Study: NCT04847063
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part of Arm 3: intraperitoneal (IP) Doxorubicin co-therapy 15 mg/m2 for 60 minutes, given at time = 0 with cisplatin
Study: NCT05247905
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT06412666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT05537233
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection placebo up to 1 mg per week in addition to standard closed-loop therapy
Study: NCT05006599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.
Study: NCT05882058
Drug: BI 764532, dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 764532, dose 1
Study: NCT05882058
Drug: BI 764532, dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 764532, dose 2
Study: NCT04938765
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of normal saline bolus will be administered to the control group over 10 mins.
Study: NCT06384456
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mL of 100mg/mL normal saline will be administered into the surgical wound prior closure.
Study: NCT04953897
Drug: ASTX727
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)